- Direction
- Unknown
- Own history
- —
- Peers
- 40th
- Persistence
- TRANSIENT
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTGILEAD SCIENCES, INC.'s latest supported as-filed period reports revenue of $8.3B. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 316.04% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.86% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 60.66% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 6.83% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 22.84% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 81.07% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 10.2%; Operating margin moved 16814 bp lower; Operating income changed across a sign change.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 61.2%; Capex / revenue moved 96 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 30.8%; Capex / revenue moved 28 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 6.8%; Operating margin moved 111 bp lower; Operating income increased 4.1%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 6.8%; Operating margin moved 111 bp lower; Operating income increased 4.1%.
3 evidence-backed componentsDebt / assets changed +840 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
GILD · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000882095-26-000039SEC ↗8-KOct 29, 2026Period Oct 29, 20260000882095-26-000037SEC ↗4Oct 16, 2026Period Oct 15, 20260001310204-26-000031SEC ↗4Oct 16, 2026Period Oct 15, 20260001782135-26-000035SEC ↗4Oct 2, 2026Period Oct 1, 20260001638643-26-000035SEC ↗4Sep 23, 2026Period Sep 22, 20260001927648-26-000005SEC ↗4Sep 16, 2026Period Sep 15, 20260001310204-26-000029SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 15, 2026Filed Oct 16, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Open Market SaleDirect | 3,000 | $156 | $468,660 | Form 4 ↗ |
| Oct 15, 2026Filed Oct 16, 2026 | Dickinson Andrew DChief Financial Officer | Open Market SaleDirect | 3,000 | $156 | $468,660 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 2, 2026 | O'Day Daniel PatrickChairman & CEO | Open Market SaleDirect | 12,000 | $148 | $1.8M | Form 4 ↗ |
| Oct 1, 2026Filed Oct 2, 2026 | O'Day Daniel PatrickChairman & CEO | Open Market SaleDirect | 3,000 | $149 | $445,880 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.operating_margin
Raw value 41.71% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 2.82% · OPTIONAL
Debt / assets changed +841 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed +376.8% from the comparable as-filed period.
Operating cash flow changed +332.0% from the comparable as-filed period.
Total assets changed -12.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed -11.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed -16814 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001782135-26-000033| Sep 22, 2026Filed Sep 23, 2026 |
| Burkhart ErinSVP, Controllership |
| Option ExerciseDirect |
| 2,223 |
| — |
| — |
| Form 4 ↗ |
| Sep 22, 2026Filed Sep 23, 2026 | Burkhart ErinSVP, Controllership | Tax WithholdingDirect | 768 | $153 | $117,251 | Form 4 ↗ |
| Sep 22, 2026Filed Sep 23, 2026 | Burkhart ErinSVP, Controllership | Option ExerciseDirect | 2,223 | — | — | Form 4 ↗ |
| Sep 15, 2026Filed Sep 16, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Open Market SaleDirect | 600 | $145 | $87,174 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 16, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Open Market SaleDirect | 800 | $144 | $115,566 | Form 4 ↗ |
| Sep 15, 2026Filed Sep 16, 2026 | Mercier JohannaChief Comm & Corp Aff Officer | Open Market SaleDirect | 1,600 | $144 | $229,907 | Form 4 ↗ |
| Sep 10, 2026Filed Sep 11, 2026 | Berger DietmarChief Medical Officer | Tax WithholdingDirect | 263 | $145 | $38,085 | Form 4 ↗ |
| Sep 10, 2026Filed Sep 11, 2026 | Berger DietmarChief Medical Officer | Option ExerciseDirect | 533 | — | — | Form 4 ↗ |
| Sep 10, 2026Filed Sep 11, 2026 | Berger DietmarChief Medical Officer | Option ExerciseDirect | 533 | — | — | Form 4 ↗ |
| Aug 26, 2026Filed Aug 27, 2026 | WELTERS ANTHONYDirector | Open Market SaleDirect | 3,402 | $148 | $504,296 | Form 4 ↗ |
| Aug 26, 2026Filed Aug 27, 2026 | WELTERS ANTHONYDirector | Option ExerciseDirect | 7,718 | $61 | $468,251 | Form 4 ↗ |
| Aug 26, 2026Filed Aug 27, 2026 | WELTERS ANTHONYDirector | Open Market SaleDirect | 3,118 | $148 | $462,432 | Form 4 ↗ |
| Aug 26, 2026Filed Aug 27, 2026 | WELTERS ANTHONYDirector | Open Market SaleDirect | 4,600 | $149 | $684,590 | Form 4 ↗ |
| Aug 26, 2026Filed Aug 27, 2026 | WELTERS ANTHONYDirector | Option ExerciseDirect | 10,282 | $61 | $630,801 | Form 4 ↗ |
| Aug 26, 2026Filed Aug 27, 2026 | WELTERS ANTHONYDirector | Open Market SaleDirect | 6,880 | $149 | $1.0M | Form 4 ↗ |
| Aug 26, 2026Filed Aug 27, 2026 | WELTERS ANTHONYDirector | Option ExerciseDirect | 7,718 | $0 | $0 | Form 4 ↗ |